发明申请
US20230045015A1 Use of Cobra neurotoxin polypeptide molecule in the treatment of nephropathy proteinuria
有权

基本信息:
- 专利标题: Use of Cobra neurotoxin polypeptide molecule in the treatment of nephropathy proteinuria
- 申请号:US17639929 申请日:2020-08-28
- 公开(公告)号:US20230045015A1 公开(公告)日:2023-02-09
- 发明人: zhankai QI , Hyatt QI
- 申请人: zhankai QI , Hyatt QI
- 申请人地址: CN Shanghai; CN Shanghai
- 专利权人: zhankai QI,Hyatt QI
- 当前专利权人: zhankai QI,Hyatt QI
- 当前专利权人地址: CN Shanghai; CN Shanghai
- 优先权: CM201910847029.6 20190903
- 国际申请: PCT/CN2020/000197 WO 20200828
- 主分类号: A61K38/17
- IPC分类号: A61K38/17 ; A61P13/12
摘要:
With years of disease progression, a small amount of albumin in the blood of nephropathy patients started to leak into the urine, however very likely to be ignored due to mild clinical symptoms or confused with proteinuria caused by hypertension and/or hyperlipidemia with progress. But when other biomarkers of renal function are also found significantly increased in urine, such as β2 microglobulin α1 microglobulin, transferrin and immunoglobulin, the renal function has been impacted by pathological changes. At present, there is no effective method except hormone for nephropathy proteinuria treatment, and long-term hormone treatment will bring many side effects to patients. If the course of disease progresses freely, more protein will leak into the urine, and the renal damage will be getting worse. Cobrotoxin polypeptide molecule can effectively reduce the leakage/proteinuria, control and delay the renal pathological progression and improve renal function by inhibiting the autoimmune inflammatory response of kidney, thus contribute significantly to the treatment of nephropathy.
IPC结构图谱:
A | 人类生活必需 |
--A61 | 医学或兽医学;卫生学 |
----A61K | 医用、牙科用或梳妆用的配制品 |
------A61K38/00 | 含肽的医药配制品 |
--------A61K38/04 | .在完全确定的序列中最多有20个氨基酸的肽;其衍生物 |
----------A61K38/17 | ..来源于动物;来源于人类 |